AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cps Technologies Corp. shares rise 1.81% after-hours following I-Mab's investment expansion and executive appointments.
ByAinvest
Monday, Sep 8, 2025 6:36 pm ET1min read
Cps Technologies Corp. rose 1.81% in after-hours trading, with I-Mab announcing an acceleration of its investment in givastomig for metastatic gastric cancers. The company plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy in Q1 2026, with additional Phase 1b cohorts to follow. I-Mab also reiterated its expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026 and plans to broaden its 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC). Additionally, Mr. Wei Fu, I-Mab’s Chairman of the Board of Directors, was appointed as Executive Chairman, supported by further executive additions.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet